本稿では、ペプチド模倣化合物と実際のペプチドの構造との類似度を評価する手法を開発し、当社の化合物が優位性を示すことが述べられています。
Visualized and Quantitative Conformational Analysis of Peptidomimetics
ACS omega, 6(40), 26601-26612 (2021)

PRISM BioLab, the Japan based biotechnology company with proprietary small molecule drug discovery technology ”PepMetics®”, today announced that it has raised a total of ¥1.3 billion in Series C funding on August 27. Read Full Press Release

PRISM BioLab provides PepMetics® (peptide mimetic small molecules) Technology for generating Hit and Lead compounds against Servier’s novel target. Read Full Press Release

PRISM Biolab provides The PRISM Library, proprietary library of peptide mimetic small molecules for screening against Merck’s novel targets Read Full Press Release

PRISM Biolab provides The PRISM Library, proprietary library of peptide mimetic small molecules for screening against Boehringer Ingelheim’s novel targets Read Full Press Release

PRISM Pharma Co.,Ltd. (“Pharma”) and its wholly owned subsidiary, PRISM BioLab Co.,Ltd.(“BioLab”), have merged as of Octorber 1,2018. BioLab succeeds all Pharma’s rights and obligations. Because those two companies were operated as one by the same management, actual business will not change at all after this merger. PRISM BioLab Co., Ltd. President & CEO Dai...